Header Logo

Connection

Stuart Levitz to Animals

This is a "connection" page, showing publications Stuart Levitz has written about Animals.
Connection Strength

1.786
  1. Specht CA, Wang R, Oliveira LVN, Hester MM, Gomez C, Mou Z, Carlson D, Lee CK, Hole CR, Lam WC, Upadhya R, Lodge JK, Levitz SM. Immunological correlates of protection mediated by a whole organism, Cryptococcus neoformans, vaccine deficient in chitosan. mBio. 2024 Aug 14; 15(8):e0174624.
    View in: PubMed
    Score: 0.065
  2. Wang R, Oliveira LVN, Hester MM, Carlson D, Christensen D, Specht CA, Levitz SM. Protection against experimental cryptococcosis elicited by Cationic Adjuvant Formulation 01-adjuvanted subunit vaccines. PLoS Pathog. 2024 Jul; 20(7):e1012220.
    View in: PubMed
    Score: 0.065
  3. Lee CK, Oliveira LVN, Akalin A, Specht CA, Lourenco D, Gomez CL, Ramirez-Ortiz ZG, Wang JP, Levitz SM. Dysregulated pulmonary inflammatory responses exacerbate the outcome of secondary aspergillosis following influenza. mBio. 2023 Oct 31; 14(5):e0163323.
    View in: PubMed
    Score: 0.061
  4. Hester MM, Oliveira LVN, Wang R, Mou Z, Lourenco D, Ostroff GR, Specht CA, Levitz SM. Cross-reactivity between vaccine antigens from the chitin deacetylase protein family improves survival in a mouse model of cryptococcosis. Front Immunol. 2022; 13:1015586.
    View in: PubMed
    Score: 0.057
  5. Yadav B, Specht CA, Lee CK, Pokrovskii M, Huh JR, Littman DR, Levitz SM. Lung eosinophils elicited during allergic and acute aspergillosis express ROR?t and IL-23R but do not require IL-23 for IL-17 production. PLoS Pathog. 2021 08; 17(8):e1009891.
    View in: PubMed
    Score: 0.053
  6. Specht CA, Homan EJ, Lee CK, Mou Z, Gomez CL, Hester MM, Abraham A, Rus F, Ostroff GR, Levitz SM. Protection of Mice against Experimental Cryptococcosis by Synthesized Peptides Delivered in Glucan Particles. mBio. 2021 02 22; 13(1):e0336721.
    View in: PubMed
    Score: 0.051
  7. Deepe GS, Buesing WR, Ostroff GR, Abraham A, Specht CA, Huang H, Levitz SM. Vaccination with an alkaline extract of Histoplasma capsulatum packaged in glucan particles confers protective immunity in mice. Vaccine. 2018 05 31; 36(23):3359-3367.
    View in: PubMed
    Score: 0.042
  8. Lionakis MS, Levitz SM. Host Control of Fungal Infections: Lessons from Basic Studies and Human Cohorts. Annu Rev Immunol. 2018 04 26; 36:157-191.
    View in: PubMed
    Score: 0.041
  9. Specht CA, Lee CK, Huang H, Hester MM, Liu J, Luckie BA, Torres Santana MA, Mirza Z, Khoshkenar P, Abraham A, Shen ZT, Lodge JK, Akalin A, Homan J, Ostroff GR, Levitz SM. Vaccination with Recombinant Cryptococcus Proteins in Glucan Particles Protects Mice against Cryptococcosis in a Manner Dependent upon Mouse Strain and Cryptococcal Species. mBio. 2017 11 28; 8(6).
    View in: PubMed
    Score: 0.041
  10. Guerra ES, Lee CK, Specht CA, Yadav B, Huang H, Akalin A, Huh JR, Mueller C, Levitz SM. Central Role of IL-23 and IL-17 Producing Eosinophils as Immunomodulatory Effector Cells in Acute Pulmonary Aspergillosis and Allergic Asthma. PLoS Pathog. 2017 01; 13(1):e1006175.
    View in: PubMed
    Score: 0.039
  11. Levitz SM. Aspergillus vaccines: Hardly worth studying or worthy of hard study? Med Mycol. 2017 Jan 01; 55(1):103-108.
    View in: PubMed
    Score: 0.038
  12. Specht CA, Lee CK, Huang H, Tipper DJ, Shen ZT, Lodge JK, Leszyk J, Ostroff GR, Levitz SM. Protection against Experimental Cryptococcosis following Vaccination with Glucan Particles Containing Cryptococcus Alkaline Extracts. mBio. 2015 Dec 22; 6(6):e01905-15.
    View in: PubMed
    Score: 0.036
  13. Levitz SM, Huang H, Ostroff GR, Specht CA. Exploiting fungal cell wall components in vaccines. Semin Immunopathol. 2015 Mar; 37(2):199-207.
    View in: PubMed
    Score: 0.033
  14. Bueter CL, Lee CK, Wang JP, Ostroff GR, Specht CA, Levitz SM. Spectrum and mechanisms of inflammasome activation by chitosan. J Immunol. 2014 Jun 15; 192(12):5943-51.
    View in: PubMed
    Score: 0.032
  15. Cole GT, Hung CY, Sanderson SD, Hurtgen BJ, W?thrich M, Klein BS, Deepe GS, Ostroff GR, Levitz SM. Novel strategies to enhance vaccine immunity against coccidioidomycosis. PLoS Pathog. 2013; 9(12):e1003768.
    View in: PubMed
    Score: 0.031
  16. Huang H, Ostroff GR, Lee CK, Specht CA, Levitz SM. Characterization and optimization of the glucan particle-based vaccine platform. Clin Vaccine Immunol. 2013 Oct; 20(10):1585-91.
    View in: PubMed
    Score: 0.030
  17. Bueter CL, Specht CA, Levitz SM. Innate sensing of chitin and chitosan. PLoS Pathog. 2013 Jan; 9(1):e1003080.
    View in: PubMed
    Score: 0.029
  18. Huang H, Ostroff GR, Lee CK, Agarwal S, Ram S, Rice PA, Specht CA, Levitz SM. Relative contributions of dectin-1 and complement to immune responses to particulate ?-glucans. J Immunol. 2012 Jul 01; 189(1):312-7.
    View in: PubMed
    Score: 0.028
  19. Levitz SM, Golenbock DT. Beyond empiricism: informing vaccine development through innate immunity research. Cell. 2012 Mar 16; 148(6):1284-92.
    View in: PubMed
    Score: 0.028
  20. Wang JP, Lee CK, Akalin A, Finberg RW, Levitz SM. Contributions of the MyD88-dependent receptors IL-18R, IL-1R, and TLR9 to host defenses following pulmonary challenge with Cryptococcus neoformans. PLoS One. 2011; 6(10):e26232.
    View in: PubMed
    Score: 0.027
  21. Bueter CL, Lee CK, Rathinam VAK, Healy GJ, Taron CH, Specht CA, Levitz SM. Chitosan but not chitin activates the inflammasome by a mechanism dependent upon phagocytosis. J Biol Chem. 2011 Oct 14; 286(41):35447-35455.
    View in: PubMed
    Score: 0.027
  22. Ramirez-Ortiz ZG, Lee CK, Wang JP, Boon L, Specht CA, Levitz SM. A nonredundant role for plasmacytoid dendritic cells in host defense against the human fungal pathogen Aspergillus fumigatus. Cell Host Microbe. 2011 May 19; 9(5):415-24.
    View in: PubMed
    Score: 0.026
  23. Huang H, Ostroff GR, Lee CK, Specht CA, Levitz SM. Robust stimulation of humoral and cellular immune responses following vaccination with antigen-loaded beta-glucan particles. mBio. 2010 Jul 20; 1(3).
    View in: PubMed
    Score: 0.025
  24. Levitz SM. Innate recognition of fungal cell walls. PLoS Pathog. 2010 Apr 22; 6(4):e1000758.
    View in: PubMed
    Score: 0.024
  25. Huang H, Ostroff GR, Lee CK, Wang JP, Specht CA, Levitz SM. Distinct patterns of dendritic cell cytokine release stimulated by fungal beta-glucans and toll-like receptor agonists. Infect Immun. 2009 May; 77(5):1774-81.
    View in: PubMed
    Score: 0.022
  26. Wozniak KL, Levitz SM. Isolation and purification of antigenic components of Cryptococcus. Methods Mol Biol. 2009; 470:71-83.
    View in: PubMed
    Score: 0.022
  27. Wozniak KL, Levitz SM. Cryptococcus neoformans enters the endolysosomal pathway of dendritic cells and is killed by lysosomal components. Infect Immun. 2008 Oct; 76(10):4764-71.
    View in: PubMed
    Score: 0.021
  28. Dan JM, Wang JP, Lee CK, Levitz SM. Cooperative stimulation of dendritic cells by Cryptococcus neoformans mannoproteins and CpG oligodeoxynucleotides. PLoS One. 2008 Apr 30; 3(4):e2046.
    View in: PubMed
    Score: 0.021
  29. Dan JM, Kelly RM, Lee CK, Levitz SM. Role of the mannose receptor in a murine model of Cryptococcus neoformans infection. Infect Immun. 2008 Jun; 76(6):2362-7.
    View in: PubMed
    Score: 0.021
  30. Ramirez-Ortiz ZG, Specht CA, Wang JP, Lee CK, Bartholomeu DC, Gazzinelli RT, Levitz SM. Toll-like receptor 9-dependent immune activation by unmethylated CpG motifs in Aspergillus fumigatus DNA. Infect Immun. 2008 May; 76(5):2123-9.
    View in: PubMed
    Score: 0.021
  31. Lam JS, Huang H, Levitz SM. Effect of differential N-linked and O-linked mannosylation on recognition of fungal antigens by dendritic cells. PLoS One. 2007 Oct 10; 2(10):e1009.
    View in: PubMed
    Score: 0.020
  32. Specht CA, Nong S, Dan JM, Lee CK, Levitz SM. Contribution of glycosylation to T cell responses stimulated by recombinant Cryptococcus neoformans mannoprotein. J Infect Dis. 2007 Sep 01; 196(5):796-800.
    View in: PubMed
    Score: 0.020
  33. Luong M, Lam JS, Chen J, Levitz SM. Effects of fungal N- and O-linked mannosylation on the immunogenicity of model vaccines. Vaccine. 2007 May 30; 25(22):4340-4.
    View in: PubMed
    Score: 0.020
  34. Yauch LE, Lam JS, Levitz SM. Direct inhibition of T-cell responses by the Cryptococcus capsular polysaccharide glucuronoxylomannan. PLoS Pathog. 2006 Nov; 2(11):e120.
    View in: PubMed
    Score: 0.019
  35. Dan JM, Levitz SM. Prospects for development of vaccines against fungal diseases. Drug Resist Updat. 2006 Jun; 9(3):105-10.
    View in: PubMed
    Score: 0.019
  36. Wozniak KL, Vyas JM, Levitz SM. In vivo role of dendritic cells in a murine model of pulmonary cryptococcosis. Infect Immun. 2006 Jul; 74(7):3817-24.
    View in: PubMed
    Score: 0.019
  37. Levitz SM, Specht CA. The molecular basis for the immunogenicity of Cryptococcus neoformans mannoproteins. FEMS Yeast Res. 2006 Jun; 6(4):513-24.
    View in: PubMed
    Score: 0.018
  38. Mansour MK, Latz E, Levitz SM. Cryptococcus neoformans glycoantigens are captured by multiple lectin receptors and presented by dendritic cells. J Immunol. 2006 Mar 01; 176(5):3053-61.
    View in: PubMed
    Score: 0.018
  39. Yauch LE, Mansour MK, Levitz SM. Receptor-mediated clearance of Cryptococcus neoformans capsular polysaccharide in vivo. Infect Immun. 2005 Dec; 73(12):8429-32.
    View in: PubMed
    Score: 0.018
  40. Lam JS, Mansour MK, Specht CA, Levitz SM. A model vaccine exploiting fungal mannosylation to increase antigen immunogenicity. J Immunol. 2005 Dec 01; 175(11):7496-503.
    View in: PubMed
    Score: 0.018
  41. Kelly RM, Chen J, Yauch LE, Levitz SM. Opsonic requirements for dendritic cell-mediated responses to Cryptococcus neoformans. Infect Immun. 2005 Jan; 73(1):592-8.
    View in: PubMed
    Score: 0.017
  42. Levitz SM. Interactions of Toll-like receptors with fungi. Microbes Infect. 2004 Dec; 6(15):1351-5.
    View in: PubMed
    Score: 0.017
  43. Yauch LE, Mansour MK, Shoham S, Rottman JB, Levitz SM. Involvement of CD14, toll-like receptors 2 and 4, and MyD88 in the host response to the fungal pathogen Cryptococcus neoformans in vivo. Infect Immun. 2004 Sep; 72(9):5373-82.
    View in: PubMed
    Score: 0.016
  44. Whelan AO, Flick-Smith HC, Walker NJ, Abraham A, Levitz SM, Ostroff GR, Oyston PCF. A glucan-particle based tularemia subunit vaccine induces T-cell immunity and affords partial protection in an inhalation rat infection model. PLoS One. 2024; 19(5):e0294998.
    View in: PubMed
    Score: 0.016
  45. Mansour MK, Yauch LE, Rottman JB, Levitz SM. Protective efficacy of antigenic fractions in mouse models of cryptococcosis. Infect Immun. 2004 Mar; 72(3):1746-54.
    View in: PubMed
    Score: 0.016
  46. Hester MM, Carlson D, Lodge JK, Levitz SM, Specht CA. Immune evasion by Cryptococcus gattii in vaccinated mice coinfected with C. neoformans. Front Immunol. 2024; 15:1356651.
    View in: PubMed
    Score: 0.016
  47. Specht CA, Lam WC, Hester MM, Lourenco D, Levitz SM, Lodge JK, Upadhya R. Chitosan-Deficient Cryptococcus as Whole-Cell Vaccines. Methods Mol Biol. 2024; 2775:393-410.
    View in: PubMed
    Score: 0.016
  48. Soto ER, Specht CA, Rus F, Lee CK, Abraham A, Levitz SM, Ostroff GR. An efficient (nano) silica - In glucan particles protein encapsulation approach for improved thermal stability. J Control Release. 2023 05; 357:175-184.
    View in: PubMed
    Score: 0.015
  49. Sephton-Clark P, McConnell SA, Grossman N, Baker RP, Dragotakes Q, Fan Y, Fu MS, Gerbig G, Greengo S, Hardwick JM, Kulkarni M, Levitz SM, Nosanchuk JD, Shoham S, Smith DFQ, Stempinski P, Timp W, Wear MP, Cuomo CA, Casadevall A. Similar evolutionary trajectories in an environmental Cryptococcus neoformans isolate after human and murine infection. Proc Natl Acad Sci U S A. 2023 01 10; 120(2):e2217111120.
    View in: PubMed
    Score: 0.015
  50. Huang C, Nong SH, Mansour MK, Specht CA, Levitz SM. Purification and characterization of a second immunoreactive mannoprotein from Cryptococcus neoformans that stimulates T-Cell responses. Infect Immun. 2002 Oct; 70(10):5485-93.
    View in: PubMed
    Score: 0.014
  51. Mambula SS, Sau K, Henneke P, Golenbock DT, Levitz SM. Toll-like receptor (TLR) signaling in response to Aspergillus fumigatus. J Biol Chem. 2002 Oct 18; 277(42):39320-6.
    View in: PubMed
    Score: 0.014
  52. Mansour MK, Levitz SM. Interactions of fungi with phagocytes. Curr Opin Microbiol. 2002 Aug; 5(4):359-65.
    View in: PubMed
    Score: 0.014
  53. Weber SM, Chen JM, Levitz SM. Inhibition of mitogen-activated protein kinase signaling by chloroquine. J Immunol. 2002 May 15; 168(10):5303-9.
    View in: PubMed
    Score: 0.014
  54. Mansour MK, Schlesinger LS, Levitz SM. Optimal T cell responses to Cryptococcus neoformans mannoprotein are dependent on recognition of conjugated carbohydrates by mannose receptors. J Immunol. 2002 Mar 15; 168(6):2872-9.
    View in: PubMed
    Score: 0.014
  55. Levitz SM. Does amoeboid reasoning explain the evolution and maintenance of virulence factors in Cryptococcus neoformans? Proc Natl Acad Sci U S A. 2001 Dec 18; 98(26):14760-2.
    View in: PubMed
    Score: 0.014
  56. Levitz SM. Cryptococcus neoformans: intracellular or extracellular? Trends Microbiol. 2001 Sep; 9(9):417-8.
    View in: PubMed
    Score: 0.013
  57. Levitz SM, Nong S, Mansour MK, Huang C, Specht CA. Molecular characterization of a mannoprotein with homology to chitin deacetylases that stimulates T cell responses to Cryptococcus neoformans. Proc Natl Acad Sci U S A. 2001 Aug 28; 98(18):10422-7.
    View in: PubMed
    Score: 0.013
  58. Shoham S, Huang C, Chen JM, Golenbock DT, Levitz SM. Toll-like receptor 4 mediates intracellular signaling without TNF-alpha release in response to Cryptococcus neoformans polysaccharide capsule. J Immunol. 2001 Apr 01; 166(7):4620-6.
    View in: PubMed
    Score: 0.013
  59. Dos Santos Dias L, Dobson HE, Bakke BK, Kujoth GC, Huang J, Kohn EM, Taira CL, Wang H, Supekar NT, Fites JS, Gates D, Gomez CL, Specht CA, Levitz SM, Azadi P, Li L, Suresh M, Klein BS, W?thrich M. Structural basis of Blastomyces Endoglucanase-2 adjuvancy in anti-fungal and -viral immunity. PLoS Pathog. 2021 03; 17(3):e1009324.
    View in: PubMed
    Score: 0.013
  60. Hoenigl M, Levitz SM, Schuetz AN, Zhang SX, Cornely OA. All You Need to Know and More about the Diagnosis and Management of Rare Mold Infections. mBio. 2021 02 23; 12(1).
    View in: PubMed
    Score: 0.013
  61. Hester MM, Lee CK, Abraham A, Khoshkenar P, Ostroff GR, Levitz SM, Specht CA. Protection of mice against experimental cryptococcosis using glucan particle-based vaccines containing novel recombinant antigens. Vaccine. 2020 01 16; 38(3):620-626.
    View in: PubMed
    Score: 0.012
  62. Lam WC, Upadhya R, Specht CA, Ragsdale AE, Hole CR, Levitz SM, Lodge JK. Chitosan Biosynthesis and Virulence in the Human Fungal Pathogen Cryptococcus gattii. mSphere. 2019 10 09; 4(5).
    View in: PubMed
    Score: 0.012
  63. Abraham A, Ostroff G, Levitz SM, Oyston PCF. A novel vaccine platform using glucan particles for induction of protective responses against Francisella tularensis and other pathogens. Clin Exp Immunol. 2019 11; 198(2):143-152.
    View in: PubMed
    Score: 0.012
  64. Khan NS, Lukason DP, Feliu M, Ward RA, Lord AK, Reedy JL, Ramirez-Ortiz ZG, Tam JM, Kasperkovitz PV, Negoro PE, Vyas TD, Xu S, Brinkmann MM, Acharaya M, Artavanis-Tsakonas K, Frickel EM, Becker CE, Dagher Z, Kim YM, Latz E, Ploegh HL, Mansour MK, Miranti CK, Levitz SM, Vyas JM. CD82 controls CpG-dependent TLR9 signaling. FASEB J. 2019 11; 33(11):12500-12514.
    View in: PubMed
    Score: 0.012
  65. Whelan AO, Flick-Smith HC, Homan J, Shen ZT, Carpenter Z, Khoshkenar P, Abraham A, Walker NJ, Levitz SM, Ostroff GR, Oyston PCF. Protection induced by a Francisella tularensis subunit vaccine delivered by glucan particles. PLoS One. 2018; 13(10):e0200213.
    View in: PubMed
    Score: 0.011
  66. Teitz-Tennenbaum S, Viglianti SP, Roussey JA, Levitz SM, Olszewski MA, Osterholzer JJ. Autocrine IL-10 Signaling Promotes Dendritic Cell Type-2 Activation and Persistence of Murine Cryptococcal Lung Infection. J Immunol. 2018 10 01; 201(7):2004-2015.
    View in: PubMed
    Score: 0.011
  67. Ketelut-Carneiro N, Ghosh S, Levitz SM, Fitzgerald KA, da Silva JS. A Dectin-1-Caspase-8 Pathway Licenses Canonical Caspase-1 Inflammasome Activation and Interleukin-1? Release in Response to a Pathogenic Fungus. J Infect Dis. 2018 01 04; 217(2):329-339.
    View in: PubMed
    Score: 0.010
  68. Scriven JE, Tenforde MW, Levitz SM, Jarvis JN. Modulating host immune responses to fight invasive fungal infections. Curr Opin Microbiol. 2017 Dec; 40:95-103.
    View in: PubMed
    Score: 0.010
  69. Levitz SM, Harrison TS, Tabuni A, Liu X. Chloroquine induces human mononuclear phagocytes to inhibit and kill Cryptococcus neoformans by a mechanism independent of iron deprivation. J Clin Invest. 1997 Sep 15; 100(6):1640-6.
    View in: PubMed
    Score: 0.010
  70. Dambuza IM, Levitz SM, Netea MG, Brown GD. Fungal Recognition and Host Defense Mechanisms. Microbiol Spectr. 2017 07; 5(4).
    View in: PubMed
    Score: 0.010
  71. Levitz SM, Tabuni A, Kozel TR, MacGill RS, Ingalls RR, Golenbock DT. Binding of Cryptococcus neoformans to heterologously expressed human complement receptors. Infect Immun. 1997 Mar; 65(3):931-5.
    View in: PubMed
    Score: 0.010
  72. Mirza Z, Soto ER, Dikengil F, Levitz SM, Ostroff GR. Beta-Glucan Particles as Vaccine Adjuvant Carriers. Methods Mol Biol. 2017; 1625:143-157.
    View in: PubMed
    Score: 0.010
  73. Upadhya R, Lam WC, Maybruck B, Specht CA, Levitz SM, Lodge JK. Induction of Protective Immunity to Cryptococcal Infection in Mice by a Heat-Killed, Chitosan-Deficient Strain of Cryptococcus neoformans. mBio. 2016 05 10; 7(3).
    View in: PubMed
    Score: 0.009
  74. Levitz SM, Mathews HL, Murphy JW. Direct antimicrobial activity of T cells. Immunol Today. 1995 Aug; 16(8):387-91.
    View in: PubMed
    Score: 0.009
  75. Wiesner DL, Specht CA, Lee CK, Smith KD, Mukaremera L, Lee ST, Lee CG, Elias JA, Nielsen JN, Boulware DR, Bohjanen PR, Jenkins MK, Levitz SM, Nielsen K. Chitin recognition via chitotriosidase promotes pathologic type-2 helper T cell responses to cryptococcal infection. PLoS Pathog. 2015 Mar; 11(3):e1004701.
    View in: PubMed
    Score: 0.008
  76. Ganesan S, Rathinam VAK, Bossaller L, Army K, Kaiser WJ, Mocarski ES, Dillon CP, Green DR, Mayadas TN, Levitz SM, Hise AG, Silverman N, Fitzgerald KA. Caspase-8 modulates dectin-1 and complement receptor 3-driven IL-1? production in response to ?-glucans and the fungal pathogen, Candida albicans. J Immunol. 2014 Sep 01; 193(5):2519-2530.
    View in: PubMed
    Score: 0.008
  77. De Jesus M, Ostroff GR, Levitz SM, Bartling TR, Mantis NJ. A population of Langerin-positive dendritic cells in murine Peyer's patches involved in sampling ?-glucan microparticles. PLoS One. 2014; 9(3):e91002.
    View in: PubMed
    Score: 0.008
  78. Levitz SM. Macrophage-Cryptococcus interactions. Immunol Ser. 1994; 60:533-43.
    View in: PubMed
    Score: 0.008
  79. Levitz SM, Dupont MP. Phenotypic and functional characterization of human lymphocytes activated by interleukin-2 to directly inhibit growth of Cryptococcus neoformans in vitro. J Clin Invest. 1993 Apr; 91(4):1490-8.
    View in: PubMed
    Score: 0.007
  80. Hurtgen BJ, Hung CY, Ostroff GR, Levitz SM, Cole GT. Construction and evaluation of a novel recombinant T cell epitope-based vaccine against Coccidioidomycosis. Infect Immun. 2012 Nov; 80(11):3960-74.
    View in: PubMed
    Score: 0.007
  81. Cohen NR, Tatituri RV, Rivera A, Watts GF, Kim EY, Chiba A, Fuchs BB, Mylonakis E, Besra GS, Levitz SM, Brigl M, Brenner MB. Innate recognition of cell wall ?-glucans drives invariant natural killer T cell responses against fungi. Cell Host Microbe. 2011 Nov 17; 10(5):437-50.
    View in: PubMed
    Score: 0.007
  82. Levitz SM. The ecology of Cryptococcus neoformans and the epidemiology of cryptococcosis. Rev Infect Dis. 1991 Nov-Dec; 13(6):1163-9.
    View in: PubMed
    Score: 0.007
  83. Jesus MD, Nicola AM, Chow SK, Lee IR, Nong S, Specht CA, Levitz SM, Casadevall A. Glucuronoxylomannan, galactoxylomannan, and mannoprotein occupy spatially separate and discrete regions in the capsule of Cryptococcus neoformans. Virulence. 2010 Nov-Dec; 1(6):500-8.
    View in: PubMed
    Score: 0.006
  84. Levitz SM, DiBenedetto DJ. Paradoxical role of capsule in murine bronchoalveolar macrophage-mediated killing of Cryptococcus neoformans. J Immunol. 1989 Jan 15; 142(2):659-65.
    View in: PubMed
    Score: 0.006
  85. Levitz SM, DiBenedetto DJ. Differential stimulation of murine resident peritoneal cells by selectively opsonized encapsulated and acapsular Cryptococcus neoformans. Infect Immun. 1988 Oct; 56(10):2544-51.
    View in: PubMed
    Score: 0.005
  86. Levitz SM, Selsted ME, Ganz T, Lehrer RI, Diamond RD. In vitro killing of spores and hyphae of Aspergillus fumigatus and Rhizopus oryzae by rabbit neutrophil cationic peptides and bronchoalveolar macrophages. J Infect Dis. 1986 Sep; 154(3):483-9.
    View in: PubMed
    Score: 0.005
  87. Herrero AB, Magnelli P, Mansour MK, Levitz SM, Bussey H, Abeijon C. KRE5 gene null mutant strains of Candida albicans are avirulent and have altered cell wall composition and hypha formation properties. Eukaryot Cell. 2004 Dec; 3(6):1423-32.
    View in: PubMed
    Score: 0.004
  88. Levitz SM, Diamond RD. Killing of Aspergillus fumigatus spores and Candida albicans yeast phase by the iron-hydrogen peroxide-iodide cytotoxic system: comparison with the myeloperoxidase-hydrogen peroxide-halide system. Infect Immun. 1984 Mar; 43(3):1100-2.
    View in: PubMed
    Score: 0.004
  89. Bellocchio S, Montagnoli C, Bozza S, Gaziano R, Rossi G, Mambula SS, Vecchi A, Mantovani A, Levitz SM, Romani L. The contribution of the Toll-like/IL-1 receptor superfamily to innate and adaptive immunity to fungal pathogens in vivo. J Immunol. 2004 Mar 01; 172(5):3059-69.
    View in: PubMed
    Score: 0.004
  90. Weber SM, Levitz SM, Harrison TS. Chloroquine and the fungal phagosome. Curr Opin Microbiol. 2000 Aug; 3(4):349-53.
    View in: PubMed
    Score: 0.003
  91. Nosanchuk JD, Shoham S, Fries BC, Shapiro DS, Levitz SM, Casadevall A. Evidence of zoonotic transmission of Cryptococcus neoformans from a pet cockatoo to an immunocompromised patient. Ann Intern Med. 2000 Feb 01; 132(3):205-8.
    View in: PubMed
    Score: 0.003
  92. Kappe R, Levitz SM, Cassone A, Washburn RG. Mechanisms of host defence against fungal infection. J Med Vet Mycol. 1992; 30 Suppl 1:167-77.
    View in: PubMed
    Score: 0.002
  93. Waldorf AR, Levitz SM, Diamond RD. In vivo bronchoalveolar macrophage defense against Rhizopus oryzae and Aspergillus fumigatus. J Infect Dis. 1984 Nov; 150(5):752-60.
    View in: PubMed
    Score: 0.001
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.